Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1

Interventions

Cyclophosphamide 39fludarabine phosphate 37Azacitidine 32fludarabine 25Whole-Body Irradiation 22Busulfan 22Tacrolimus 21Antilymphocyte Serum 21Mycophenolic Acid 19Filgrastim 18Methotrexate 16Melphalan 15Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Cytarabine 13venetoclax 12thymoglobulin 12Cyclosporine 12Thiotepa 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 8Rituximab 7Radiotherapy 7Methylprednisolone 7Decitabine 7Clofarabine 7Lenalidomide 6Stem Cell Transplantation 5Sirolimus 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myelodysplastic Syndromes × quisinostat × Clear all
NCT00676728 2012-09-14

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Terminated
10 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡